Company performance
Add to research
Current Price
as of Apr 21, 2025$14.46
P/E Ratio
N/A
Market Cap
$2.46B
Description
Add to research
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Metrics
Add to research
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryBiotechnology
- TickerIMVT
- Price$14.46-4.55%
Trading Information
- Market cap$2.46B
- Float40.22%
- Average Daily Volume (1m)2,301,205
- Average Daily Volume (3m)1,818,332
- EPS-$2.62
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$111.12M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$114.20M
- EV$3.26B
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B6.04
- Debt/Equity0.01
Documents
Add to research
SEC Filings
Factset Street Account